Site icon The Invincible India

Startup Deep Dive : Thyrocare Technologies — the listed lab founder who sold to a startup and lost on the reinvestment

The Invincible India
The Invincible India Startup Deep Dive featured graphic for Thyrocare.

Thyrocare Technologies is valued at roughly ₹8,902 crore ($927 million) on the stock exchanges today, yet the man who built it from a ₹1-lakh provident-fund withdrawal no longer runs it and does not sit on its board. Dr A. Velumani turned a single-disease testing lab into only the second diagnostics company to list on India’s stock exchanges, then in June 2021 sold control to a loss-making online pharmacy startup that had never operated a single laboratory of its own.

That contradiction — a listed, profitable, three-decade-old company handed to a cash-burning startup — is the spine of this piece. It also explains why Thyrocare’s stock now carries a risk that has nothing to do with blood tests: a pledge on its promoter’s shares, tied to the debt of a parent company whose own valuation has been marked down by outside investors. Along the way there is a founder who reinvested his exit money into that same startup and says he lost ₹1,400 crore doing it, two rounds of regulatory bans during the one event that should have been Thyrocare’s biggest opportunity, and a business that still runs on a model most of its wellness-package customers never see: hospitals and doctors, not walk-in patients, generate roughly three-quarters of its revenue.

Quick facts

Company Thyrocare Technologies Limited
Founded 1996, in a rented lab in Byculla, Mumbai
Founder Dr A. Velumani, a former scientist at the Bhabha Atomic Research Centre (BARC)
Businesses Centralised diagnostic testing and preventive-wellness packages (Aarogyam brand), sold via a franchisee network
Latest FY revenue ₹829 crore, FY26 (year to March 2026)
Latest FY profit ₹163 crore net profit, FY26
Listed NSE and BSE, 9 May 2016 (BSE code 539871, NSE: THYROCARE)
Market value ₹8,902 crore as of 25 September 2026
Key shareholders / CEO Docon Technologies (an API Holdings/PharmEasy subsidiary) holds the controlling promoter stake; Rahul Guha is Chairman, CEO and MD

What they do

Thyrocare runs a centralised laboratory business: it does not chase patients through owned clinics the way a hospital chain does, it processes blood, urine and other samples sent in by a network of franchised collection points, hospitals, local pathology labs and individual doctors, then returns a report. Its original and still-largest customer base is other healthcare providers who need reliable, cheap, high-volume test processing rather than a diagnostics brand of their own. Alongside that referral business it sells directly to consumers through preventive health-checkup packages branded Aarogyam, which bundle anywhere from a handful of tests to over a hundred into a single price. The company says it now offers more than 900 individual tests and nearly 300 profiles, including 43 Aarogyam wellness packages, as per its own investor disclosures.

The origin

Velumani spent 14 years at the Bhabha Atomic Research Centre, first as a laboratory assistant and later as a scientist, working with radioimmunoassay techniques used to measure thyroid hormones. He watched how expensive and inconsistent thyroid testing was for ordinary Indian patients at the time, most of whom had no reliable, affordable way to get tested at all. In 1995 he left the security of a government job, and in 1996 used roughly ₹1 lakh drawn from his provident fund to rent a small lab space in Byculla, Mumbai. His wife, Sumathi, left her job at the State Bank of India to become the company’s first employee.

The founding bet was narrow by design. Rather than offering a broad diagnostics menu from day one, Thyrocare built its entire lab and its entire business model around one test category, thyroid profiles, running them at a volume and cost per test that no single hospital lab could match. That volume-first, one-category focus was the founding insight: centralise everything expensive (equipment, reagents, quality control) in one place, and let a distributed network of collection partners feed it samples. Only once that hub-and-spoke model proved itself on thyroid testing did the company widen into the broader preventive and diagnostic-testing catalogue it runs today.

The struggle years

The model that made Thyrocare efficient also made it fragile at the edges, and two episodes exposed that in public. The first was internal and governance-driven. In September 2019, Thyrocare’s own audit committee reviewed and rejected an offer from Velumani, then still chairman, managing director and CEO, to personally buy back Nueclear Healthcare, the company’s wholly owned imaging and radiology subsidiary, from the listed entity. The committee’s stated reasoning, reported by Business Standard on 23 September 2019, was that the subsidiary’s long payback period meant the deal did not serve minority shareholders, and that pursuing it risked diverting the founder’s own attention from the core business. A related-party proposal from the company’s own founder being turned down by its own board is not the kind of setback a growth story usually advertises, but it happened in the open, on stock-exchange disclosure.

The second came at the worst possible moment: the one event that should have been an unambiguous windfall for a diagnostics company. As COVID-19 testing volumes exploded in 2020, Thyrocare scaled from roughly 200 tests a day in March to about 40,000 a day within months, and it went on to complete more than a million COVID-related tests by the end of that year, according to its own investor disclosures cited in market reports. But quality-control problems came with that speed. Mumbai’s civic body issued a show-cause notice and a testing suspension in April 2020 over incomplete or incorrect patient information in Thyrocare’s COVID reports; Panvel’s municipal corporation ordered it to stop testing in May 2020 over false-positive results; Navi Mumbai’s civic body sought cancellation of its registration in June 2020 after report discrepancies were linked to a patient death; Thane banned the company the same month for false positives; and a Pune facility was barred in July 2020 for the same reason, as reported by Hindustan Times and Business Standard through 2020. Four separate municipal bodies suspending or banning the same diagnostics company inside four months, during the single biggest demand spike in its history, is not a footnote — it is the clearest evidence that the centralised, high-volume model has a real quality-control ceiling when it is pushed hard and fast.

The turning point

On 26 June 2021, API Holdings, the parent company of online pharmacy PharmEasy, agreed to acquire a 66.1% controlling stake in Thyrocare from Velumani and the promoter group for ₹4,546 crore, a deal TechCrunch valued at roughly $613.5 million at the prevailing exchange rate, with an additional open-offer component for public shareholders taking the total transaction size past ₹6,300 crore, as reported by ETV Bharat and TechCrunch on the day the deal was announced. It made Thyrocare the first listed Indian company to be acquired by a venture-backed startup, and it ended Velumani’s 25-year run at the company he had built from a rented lab. He signed his resignation the same day he signed the share purchase agreement.

What happened on the other side of that transaction is the part most coverage of the deal leaves out. Velumani has since said, in comments reported by Forbes India and repeated across Indian business media in 2024, that he reinvested roughly ₹1,500 crore of his exit proceeds back into PharmEasy itself, taking a stake of around 5% in the very company that had just bought him out, hoping to ride its planned public listing. That listing never happened at the valuation PharmEasy had been chasing: independent fund manager Janus Henderson marked its own holding in PharmEasy down to imply a company valuation of about $2.8 billion in 2023, roughly half of what PharmEasy had been valued at in 2021. Velumani has publicly said he lost roughly ₹1,400 crore on that reinvestment, calling his own decision “greedy” in a widely reported 2024 interview. A founder who correctly priced his exit ended up mispricing his next bet by almost the same amount he had just been paid.

The money behind it

Thyrocare’s capital history looks unlike most startup deep dives in this series: it was bootstrapped for two decades, went public rather than raising private venture rounds, and its most consequential “backer” turned out to be its acquirer.

How it makes money

Strip away the consumer-facing wellness-package marketing and Thyrocare is, at its core, a high-volume, low-unit-cost testing factory that sells processing capacity to other healthcare providers.

The numbers

Thyrocare’s revenue dipped as pandemic-era testing volumes faded, then recovered on the back of a rebuilding wellness and chronic-disease testing business.

Metric (₹ crore) FY23 FY24 FY25 FY26
Revenue 527 572 687 829
EBITDA 123 140 190 262
Net profit (PAT) 64 69 91 163

Where the money comes from

Two splits matter for Thyrocare: how revenue divides between channels, and how it divides between test categories. Both point the same way — toward the unglamorous, high-volume core rather than the branded consumer product.

The risks

The takeaway

Thyrocare’s real lesson is not about diagnostics at all. It is that the skill that builds a category is not automatically the skill that knows what to do with the money once you have been paid for it. Velumani correctly read a gap in Indian healthcare in 1996, built a genuinely differentiated low-cost, high-volume model around it, survived a public governance dispute and a public quality-control crisis, and negotiated an exit that valued his company at multiples of what he had put in. Then, by his own account, he handed a large share of those proceeds straight back into the very acquirer that had just bought him out, on the strength of a listing that never arrived at the price he expected, and it cost him nearly as much as he had just been paid. Building the thing and knowing what to do after you have sold it are two different disciplines, and success at one says nothing about competence at the other.

Frequently asked questions

Is Thyrocare still owned by its founder, Dr A. Velumani?

No. Velumani sold his 66.1% controlling stake to API Holdings, the parent of PharmEasy, for ₹4,546 crore in June 2021 and resigned from the company the same day, as reported by TechCrunch and ETV Bharat on 25-26 June 2021.

What kind of tests does Thyrocare actually run?

Thyrocare offers more than 900 individual diagnostic tests and close to 300 test profiles, spanning routine pathology through to preventive wellness packages sold under its Aarogyam brand, processed centrally through a hub-and-spoke laboratory network rather than at each collection point.

Is Thyrocare profitable?

Yes. The company reported a consolidated net profit of ₹163 crore on revenue of ₹829 crore for FY26 (year to March 2026), up 81% and 21% year-on-year respectively, according to its results reported by EquityBulls and Medical Buyer in April-May 2026.

Who controls Thyrocare now?

Docon Technologies, a subsidiary of API Holdings (PharmEasy’s parent), is the controlling promoter, holding roughly 60.9% of the company as of mid-2026 before a partial pledge release in August 2026 and a reported 10% stake sale in late 2025 reduced its encumbered and total holding.

Why does Thyrocare’s share price carry PharmEasy-related risk?

Because a large portion of the promoter’s Thyrocare shares were pledged to secure debt raised by API Holdings, PharmEasy’s parent. If API Holdings were to miss a payment or face a credit event, lenders could sell those pledged shares in the open market, which is a risk specific to Thyrocare’s ownership structure rather than its underlying diagnostics business.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.

Exit mobile version